Chronic conditions and cancer at the end of life

Cancer and Chronic Conditions: Addressing the Problem of Multimorbidity in Cancer Patients and Survivors

Volumn , Issue , 2016, Pages 455-475

  Currow, David C ^a   Phillips, Jane L ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Chronic illness; Chronic obstructive pulmonary disease; Co morbid illness; Diabetes; End of life care; Heart failure; Renal failure

Indexed keywords

EID: 85017654910     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-981-10-1844-2_15     Document Type: Chapter

References (37)

1. Bayliss EA, Reifler LM, Zeng C et al (2014) Competing risks of cancer mortality and cardiovascular events in individuals with multimorbidity. J Comorbidity 4(1):29-36
2. Clayton JM, Hancock KM, Butow PN et al (2007) Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Med J Aust 186(12):S77-S108
3. Currow DC, Clark K, Kamal A et al (2015) The population burden of chronic symptoms that substantially predate the diagnosis of a life-limiting illness. J Palliat Med 18(6):480-485
4. Rushton M, Clark R, Brideson G, Damarell R (2015) The effectiveness of non-pharmacological interventions for the management of cancer treatment-induced cardiotoxicity: a systematic review protocol. JBI Database Syst Rev Implementation Rep 13(5):53-73
5. Hunt SA, Abraham WT, Chin MH et al (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). American College of Cardiology. Available at: http://www.acc.org/clinical/guidelines/failure//index.pdf
6. Kutner JS, Blatchford PJ, Taylor DH Jr et al (2015) Safety and benefit of discontinuation statin medications in the setting of advanced life-limiting illness. JAMA Int Med 175(5):691-700
7. Gadoud A, Jenkins SM, Hogg KJ (2013) Palliative care for people with heart failure: summary of current evidence and future direction. Palliat Med 27(9):822-828
8. Phillips JL, Johnson M, Currow DC (2015) Heart failure and palliative care: are we there yet? Cardiol Today 5(1):13-16
9. Goodlin SJ (2009) Palliative care in congestive heart failure. J Am Coll Cardiol 54(5):386-396
10. Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC (2007) Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail 9(5):440-449
11. Australian Health Ministers’ Advisory Council (2011) A national framework for advance care directives. Available online at: www.ahmac.gov.au.AHMAC (Sep 2011)
12. NSW Agency of Clinical Innovation (2014) NSW guidelines for deactivation of implantable cardioverter defibrillators at the end of life. NSW Health, Sydney
13. Cancer Institute NSW (2010) eviQ: Cancer treatments online. https://www.eviq.org.au/. Accessed on 25 May 2010
14. Jarkowski A, Glode AE, Spangenthal EJ, Wong MK (2011) Heart failure caused by molecularly targeted therapies for cancer. Pharmacotherapy 31(1):62-75
15. Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6):1376-1384
16. Murtagh FE, Addington-Hall J, Higginson IJ (2007) The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 14(1):82-99
17. Giannaki CD, Hadjigeorgiou GM, Karatzaferi C et al (2014) Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int 85(6):1275-1282
18. Lichtman SM, Wildiers H, Launay-Vacher V et al (2007) International society of geriatric oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43(1):14-34
19. Janus N, Thariat J, Boulanger H et al (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21(7):1395-1403
20. Australian Adult Cancer Pain Management Guideline Working Party (2014). Cancer pain management in adults. Cancer Council Australia, Sydney (2015)
21. Peterson SJ, Braunschweig CA (2016) Prevalence of sarcopenia and associated outcomes in the clinical setting. Nutr Clin Pract 31(1):40-48
22. Beuers U, Boberg KM, Chapman O et al (2009) EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 51(2):237-267
23. Runyon BA (ed) (2012) Management of adult patients with ascites due to cirrhosis: update 2012. American Association for the Study of Liver Disease. _documents/141020_Guideline_Ascites_4UFb_2015.pdf
24. D’Mello C, Swain MG (2014) Liver-brain interactions in inflammatory liver diseases: implications for fatigue and mood disorders. Brain Behav Immun 35:9-20
25. https://www.aasld.org/sites/default/files/guideline_documents/hepaticencephenhanced.pdf
26. Field KM, Michael M (2008) Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol 9:1181-1190
27. Verbeek RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64(12):1147-1161
28. Ekstrom M, Nilsson F, Abernethy AP, Currow DC (2015) Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thoracic Soc 12(7):1079-1092
29. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC (2014) Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 348:g445
30. Wilcock A, Maddocks M, Lewis M, England R et al (2008) Symptoms limiting activity in cancer patients with breathlessness on exertion: ask about muscle fatigue. Thorax 63(1):91-92
31. Therapeutic Guidelines (2010) Palliative care (version 3 ed). Therapeutic Guidelines Limited, Melbourne
32. American Cancer Society (2014) HIV infection, AIDS, and cancer. http://www.cancer.org/acs/groups/cid/documents/webcontent/002295-pdf.pdf
33. HIV Drug Interactions http://www.hiv-druginteractions.org
34. Stevenson J, Miller C, Abernethy AP, Currow DC (2004) Managing comorbidities in patients at the end of life. Br Med J 329(7471):909-912
35. Olver I (ed) (2010) The MASCC textbook of cancer supportive care and survivorship. Springer, Berlin
36. Clark K, Currow DC (2007) Emergencies in palliative medicine (Ch 9). In: Walsh D et al (eds) Textbook of palliative medicine. Elsevier, Oxford University Press
37. Cherny NI, Fallon MT, Kaasa S, Portenoy R, Currow DC (eds) (2015) Oxford textbook of palliative medicine 5th ed.